The effect of erythropoetin on Multiple Sclerosis
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT2013081914407N1
- Lead Sponsor
- Tehran university of medical science research assistance
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
definite diagnosis of MS; age between 18 and 45 years old and motor force 3/5 or less at presentation.
Exclusion criteria: pregnancy; brestfeeding; history of diabetes mellitus, hypertension, hyperlipidmia, heavy cigarette smoking, ischemic heart disease, myocardial infarction, cerebovasculaar accident; family history of ischemic heart disease and /or cerebrovascular accident before 45 years; presence of thrombocytosis; presence of polycytemia(hematocrite above 50% in males and above 45% in females); presence of CRF(chronic renal failure); history of any vasculitis or collagen vascular disease; use of contraceptive medication; use of iron substitution; past history of thromboembololic events and any kind of malignancy(treated or untreated).
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EDSS. Timepoint: Before intervention, one, two three months after intervention. Method of measurement: Examination.;Ambulatory Index. Timepoint: Before intervention, one, two three months after intervention. Method of measurement: Examination.;MRI. Timepoint: Before intervention and three months after intervention. Method of measurement: Visual.
- Secondary Outcome Measures
Name Time Method Blood Pressure. Timepoint: Before intervention, five day and one and three months after intervention. Method of measurement: Sphygmomanometer.;RBC count. Timepoint: Before intervention, five day and three months after intervention. Method of measurement: Laboratory.